Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878441 | 0.87 | BTN3A1 (0.43) | BTN3A1ANPEPLAP3ELANEPKM | |
| SCHEMBL643837 | 0.83 | BTN3A1 (0.40) | BTN3A1ANPEPLAP3ELANEPKM | |
| SCHEMBL5996997 | 0.83 | BTN3A1 (0.40) | BTN3A1ANPEPLAP3ELANEPKM | |
| SCHEMBL27559223 | 0.81 | ANPEP (0.48) | ANPEPLAP3ELANESRCPRTN3 | |
| SCHEMBL27559224 | 0.81 | ANPEP (0.48) | ANPEPLAP3ELANESRCPRTN3 | |
| SCHEMBL877722 | 0.75 | TDP1 (0.41) | BTN3A1ANPEPLAP3ELANESRC | |
| SCHEMBL6708631 | 0.74 | LMNA (0.42) | LMNATDP1NPSR1MAPK1 | |
| SCHEMBL7807907 | 0.74 | KMT2A (0.40) | BTN3A1HTTL3MBTL1LMNAMAPK1 | |
| SCHEMBL10004082 | 0.73 | CA1 (0.38) | PKMHTTHPGD | |
| SCHEMBL23470935 | 0.72 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANESRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904365-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2022-09-07 | — | — | EP | disclosed |
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| EP-2955190-B1 | Chemical compounds | NuCana plc (GB) | 2018-03-28 | — | — | EP | disclosed |
| EP-1646639-B1 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | NUCANA BIOMED LTD (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3040340-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-07-06 | — | — | EP | disclosed |
| EP-2955190-A2 | Chemical compounds | NuCana BioMed Limited (GB) | 2015-12-16 | — | — | EP | disclosed |
| EP-2099461-B1 | LNA NUCLEOSIDE PHOSPHORAMIDATES | SANTARIS PHARMA AS (DK) | 2012-03-28 | — | — | EP | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| EP-2099461-A2 | LNA NUCLEOSIDE PHOSPHORAMIDATES | Santaris Pharma A/S (DK) | 2009-09-16 | — | — | EP | disclosed |
| WO-2007054100-A2 | LNA NUCLEOSIDE PHOSPHORAMIDATES | SANTARIS PHARMA A/S (DK) | 2007-05-18 | — | — | WO | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | BTN3A1 3438/4885ANPEP 334/4885LAP3 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.